Case report. A rare case of triple-hit diffuse large B-cell lymphoma of the parotid gland in a patient with Sjogren’s syndrome

Abstract

BACKGROUND. Primary malignant lymphomas of the salivary gland are rare, accounting for 2% of salivary gland tumors and 5% of all extranodal lymphomas. The clinical presentation is not particularly characteristic, a feature that usually leads to diagnostic and treatment delays.

CASE REPORT. We report a case of a parotid gland triple-hit diffuse large B-cell (DLBCL) lymphoma associated with follicular lymphoma in a 76-year-old female patient with a unique personal history, which included a diagnosis of Sjogren Syndrome and exposure to a toxic working environment with pesticides. Diffuse large B-cell lymphomas are uncommon given the fact that most lymphoid malignancies are low-grade lymphomas, with MALT (mucosa associated lymphoid tissue) lymphomas being the most common. Triple-hit DLBCL are extremely rare and the diagnosis can be challenging. Parotidectomy, as the first step, must be followed by histopathology and immunohistochemistry for final diagnosis and treatment.

CONCLUSION. This case highlights the fact that B-cell lymphoma in the salivary gland can be unrecognized due to unspecific symptoms and requires immunohistochemistry studies for confirmation. It is important to recognize triple-hit lymphoma due to its worse prognosis and differentiated treatment. Patients with Sjogren syndrome have additional risk factors for progression to lymphoma.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Sarris A.H., Papadimitrakopoulou V., Dimopoulos M.A., Smith T., Pugh W., Ha C.S., McLaughlin P., Callender D., Cox J., Cabanillas F. - Primary parotid lymphoma: the effect of International Prognostic Index on outcome. Leuk Lymphoma., 1997;26(1-2):49-56.

  • 2. Gleeson M.J., Bennett M.H., Cawson R.A. - Lymphomas of salivary glands. Cancer, 1986;58(3):699-704.

  • 3. Harris N.L. - Lymphoid proliferations of the salivary glands. Am J Clin Pathol., 1999;111(1 Suppl 1):S94-S103.

  • 4. Ampil F.L., Misra R.P. - Malignant lymphoma of the salivary gland: Case reports and review of the literature. Radiat Med., 1987;5(1):20-26.

  • 5. Ekstrom Smedby K., Vajdic C.M., Falster M., Engels E.A., Martinez-Maza O., Turner J., et al. - Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood, 2008;111(8):4029-4038. doi:

    • Crossref
    • Export Citation
  • 6. Tomita N. - BCL2 and MYC dual-hit lymphoma/leukemia. J Clin Exp Hematop., 2011;51(1)7-12.

  • 7. Almothafar B., Wong L., Noorafidah M.D. - Primary large B cell lymphoma of the parotid gland: Case report. JUMMEC, 2011;14(1):26-30.

  • 8. Samanta M., Ratha B., Mallik A.K., Mishra M. - Disseminated non-Hodgkin’s lymphoma presenting as unilateral parotid gland enlargement with facial nerve palsy. Med J DY Patil Univ., 2014;7(5):683-685.

  • 9. Dispenza F., Cicero G., Mortellaro G., Marchese D., Kulamarva G., Dispenza C. - Primary non-Hodgkins lymphoma of the parotid gland. Braz J Otorhinolaryngol., 2011;77(5):639-644.

  • 10. Faur A., Lazăr E., Cornianu M., Dema A., Lăzureanu C., Mureşan A., Taban S. - Primary malignant non-Hodgkin’s lymphoma of salivary glands. Rom J Morphol Embryol., 2009;50(4):693-699.

  • 11. Kim C.S., Choi Y.D., Choi J.S., Bae E.H., Ma S.K. , Kim S.W. - EBV-positive diffuse large B-cell lymphoma in a patient with primary Sjogren’s syndrome and membranous glomerulonephritis. BMC Nephrol., 2012;13:149. doi:

    • Crossref
    • Export Citation
  • 12. Tadashi T. - Primary diffuse large B-cell lymphoma of the submandibular gland. Int J Clin Exp Pathol., 2012;5(2):179-181.

  • 13. Freeman C., Berg J.W., Cutler S.J. - Occurrence and prognosis of extranodal lymphomas. Cancer, 1972;29(1):252-260.

  • 14. Choi W.W., Weisenburger D.D., Greiner T.C., Piris M.A., Banham A.H., Delabie J., Braziel R.M., Geng H., Igbal J., Lenz G., et al. - A new immunostain algorithm classifies diffuse large B- cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res., 2009;15(17):5494-5502. doi:

    • Crossref
    • Export Citation
  • 15. Coutinho R., Clear A.J., Owen A., Wilson A., Matthews J., Lee A., Alvarez R., Gomez da Silva M., Cabecadas J., Calaminici M., Gribben J.G. - Poor concordance among nine immunohistochemistry classifiers of cell-oforigin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res., 2013;19(24):6686-6695. doi:

    • Crossref
    • Export Citation
  • 16. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Muller-Hermelink H.K., Campo E., Braziel R.M., Jaffe E.S., Pan Z., Farinha P., Smith L.M., Falini B., Banham A.H., Rosenwald A., Staudt L.M., Connors J.M., Armitage J.O., Chan W.C. - Confirmation of the molecular classification of diffuse large B- cell Lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004;103(1):275-282. Epub 2003 Sep 22.

  • 17. Hwang H.S., Park C.S., Yoon D.H., Suh C., Huh J. - High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol., 2014;38(8):1046-1057. doi:

    • Crossref
    • Export Citation
  • 18. Benesova K., Forsterova K., Votavova H., Campr V., Stritesky J., Velenska Z., Prochazka B., Pytlik R., Trneny M. - The Hans algorithm failed to predict outcome in patients with diffuse large B -cell lymphoma treated with Rituximab. Neoplasma, 2013;60(1):68-73. doi:

    • Crossref
    • Export Citation
  • 19. Gutierrez- Garcia G., Cardesa-Salzmann T., Climent F., Gonzalez-Barca E., Mercadal S., Mate J.L., Sancho J.M., Arenillas L., et. al. - Geneexpression profiling and not immunophenotypic algorithms predicts prognosis in patient with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood, 2011;117(18):4836-4843. doi:

    • Crossref
    • Export Citation
  • 20. Sarkozy C., Traverse-Glehen A., Coiffier B. - Double-hit and double-protein- expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol., 2015;16(15):e555-e567. doi:

    • Crossref
    • Export Citation
  • 21. Lu T.X., Fan L., Wang L., Wu J.Z., Miao K.R., Liang J.H., Gong Q.X., Wang Z., Young K.H., Xu W., Zhang Z.H., Li J.Y. - MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget, 2015;6(21):18374-18388. doi:

    • Crossref
    • Export Citation
  • 22. Motllo C., Grau J., Junca J., Ruiz N., Mate J.L., Orna E., Navarro J.T., Vives S., Sancho J.M., Esteban D., Granada I., Feliu E., Ribera J.M., Milla F. - Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma. Cancer Genet Cytogenet., 2010;203(2):328-332. doi:

    • Crossref
    • Export Citation
  • 23. Pedersen M.O., Gang A.O., Poulsen T.S., Knudsen H., Lauritzen A.F., Nielsen S.L., Gang U.O., Nargaard P. - Double-hit BCL2/MYC translocations in a consecutive chohort of patients with large B-cell lymphoma - a single centre’s experience. Eur J Haematol., 2012;89(1):63-71. doi:

    • Crossref
    • Export Citation
  • 24. Savage K.J., Johnson N.A., Ben -Neriah S., Connors J.M., Sehn L.H., Farinha P., Horsman D.E., Gascoyne R.D. - MUC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood, 2009;114(17):3533-3537. doi:

    • Crossref
    • Export Citation
OPEN ACCESS

Journal + Issues

Search